TVTX

47.0002.69%
JA

John A. Orwin

Independent Director

Mr. John A. Orwin, M.B.A., is Chair of the Board at Synthekine Inc. from February 2026. He is Venture Partner of Samsara BioCapital LLC from June 2024. He joined the Samsara BioCapital LLC in June 2024. He serves as a Independent Non-Employee Director at First Tracks Biotherapeutics, Inc. and also its Independent Chairman of the Board. He is Founder and Director of Ambrosia Biosciences Inc. He serves as Chairman of the Board for Nested Therapeutics since February 2024. He served as Independent Chairman of the Board of AnaptysBio, Inc. since September 15, 2023 until August 2026. He is Independent Director at AnaptysBio, Inc. since September 15, 2023. He had been President, Chief Executive Officer at Atreca, Inc. since April 19, 2018 until June 2024 and serves as its Principal Financial Officer since September 22, 2023. He has been Director at Atreca, Inc. since April 19, 2018. He served as Independent Chairman of the Board at Cargo Therapeutics, Inc. since September 2022 until August 18, 2025 and served as its Director until August 18, 2025. Mr. Orwin had been a Director of Seagen Inc. since January 13, 2014 until December 2023. Mr. Orwin has experience as a senior executive at leading pharmaceutical and biotechnology companies, including Atreca, Inc. Relypsa, Inc. Affymax, Inc. Genentech, Inc. and Johnson & Johnson. Prior to joining Atreca, Mr. Orwin served as the Chief Executive Officer of Vifor Pharma, Inc. (formerly known as Relypsa, Inc.) since June 17, 2013 until March 2017 and served as its President since June 2013 until September 2016. He served as a Director of Vifor Pharma, Inc. (formerly known as Relypsa, Inc.). since June 2013 until September 2016. Mr. Orwin is a biotechnology and pharmaceutical industry veteran with executive-level experience at publicly-held and private biotechnology and large pharmaceutical companies, including significant experience in commercial launch and sales support. He served as the Chief Executive Officer of Affymax, Inc. since February 1, 2011 until May 15, 2013. Mr. Orwin served as the President and Chief Operating Officer at Affymax, Inc. from joining it in April 2010 to January 2011. Mr. Orwin served as Senior Vice President of Sales & Marketing for Bio Oncology of Genentech, Inc. since January 17, 2007 until April 2010. He was Vice President and then Senior Vice President of the BioOncology Business Unit (2005-2010). Mr. Orwin served as Vice President of Bio Oncology at Genentech, Inc. since January 2005 until January 17, 2007. He served as a Vice President of Human EGF-Receptor Family Product Sales and Marketing at Genentech, Inc. since December 2004. He was responsible for leadership and development of the Human EGF-Receptor family product portfolio, including sales and marketing activities and the business' life cycle plans. From 2001 to 2005, Mr. Orwin served in various executive level positions at Johnson & Johnson. He served in Johnson & Johnson's Ortho Biotech division, where he served as Franchise Vice President, Oncology of the Tibotec Therapeutics group. He has held Senior Marketing and Sales Positions with Schering-Plough Corporation, Rhone-Poulenc Rorer Pharmaceuticals, Sangstat Medical Corporation and Alza Pharmaceuticals. Mr. Orwin was Senior Director, Oncology Marketing at ALZA Pharmaceuticals, Vice President, Marketing at Sangstat Medical Corporation; Marketing Director, Asthma at Rhone-Poulenc Rorer Pharmaceuticals and Product Manager, Schering Oncology/Biotech at Schering-Plough Corporation. He served as the Chairman of Affymax, Inc. from June 6, 2013 to November 2014 and served as its Director since February 2011. He has an Independent Director of Travere Therapeutics, Inc. since March 23, 2017. He serves as Director of Biotechnology Innovation Organization. He served as an Independent Director of Array BioPharma Inc. since November 6, 2012 until July 30, 2019. He had been an Independent Director of NeurogesX, Inc. since November 19, 2009 until July 2013. He has been a Director and a Member of Emerging Companies Section Governing Board at Biotechnology Industry Organization since July 2011. He served as a Director of Affymax, Inc. from February 1, 2011 to November 2014. Mr. Orwin holds a Master of Business Administration from the Stern School of Business, New York University and a Bachelor of Arts Degree in Economics from Rutgers University.

Positions